English Korean Chinese
ホーム > 市場調査レポート > 医薬品 > 神経疾患 > 米国の多発性硬化症市場
カテゴリ
医薬品 (4962)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (181)
感染症 (353)
規制環境 (132)
後発医薬品 (135)
骨疾患 (37)
処方薬 (158)
神経疾患 (174)
精神疾患 (89)
製薬企業関連 (531)
創薬 (1523)
糖尿病 (192)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

米国の多発性硬化症市場

U.S. Multiple Sclerosis Markets

発行 Frost & Sullivan
出版日 2007年09月 商品コード 56326
ページ情報 英文 77 Pages
価格
US$ 6,000 換算 ¥ 482,820 (税抜) Web Access (Regional License)
US$ 6,500 換算 ¥ 523,055 (税抜) Hard Copy & Web Access (Regional License)


原文目次

Abstract

This research service provides revenue forecasts, market shares, projected prevalence and treated populations, market trends, and existing and emerging therapeutics. There is a competitive and product analysis of the major market participants and products with competitive metrics for major and emerging companies.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • Introduction

2. MARKET INTRODUCTION

Introduction

  • Multiple Sclerosis
  • Scope and Segmentation
  • Research Methodology

Disease Overview

  • Causes of Multiple Sclerosis
  • Classification of Multiple Sclerosis
  • Treatment Options

Market Overview

  • Market Engineering Measurements
  • Market Trends

3. MARKET ANALYSIS

Product Analysis

  • Interferons
  • Copaxone
  • Tysabri
  • Novantrone
  • Pipeline Drugs

Patient Forecasts

  • Total Patient Forecasts
  • Patient Forecast by Product

Revenue Forecasts

  • Total Market Revenue Forecasts
  • Revenue Forecasts by Product

Competitive Analysis

  • Competitive Structure
  • Company Market Share

Competitve Metrics

  • Methodology and Metrics
  • Biogen Idec
  • Teva Pharmaceuticals
  • EMD Serono
  • Bayer Schering Pharma
  • Emerging Companies

4. DECISION SUPPORT DATABASES

Demographic Indicators

  • Total Population

Market Indicators

  • World Multiple Sclerosis Prevalence
  • U.S. Multiple Sclerosis Prevalence
  • U.S. Multiple Sclerosis Incidence
  • Pharmaceutical R&D Expenditure
Back to Top